What happened to Peptide Sciences?
On March 6, 2026, Peptide Sciences — the largest research peptide vendor in the United States by web traffic — stopped operating. No prior notice went out to customers or industry partners. The website replaced its catalog with a brief shutdown message. Orders that had not yet shipped were left in limbo.
Before closing, Peptide Sciences was pulling roughly $7.4 million per month in revenue and receiving close to 990,000 monthly visitors based on third-party analytics data. They had built that position over more than a decade, with a catalog of over 190 research compounds covering growth hormone secretagogues, metabolic peptides, tissue repair factors, cognitive research compounds, and longevity-related peptides. By raw scale, they were the most recognizable name in the space.
The closure landed hard on the research community. Customer service went dark within days. Researchers got no email notifications, no fulfillment timelines, no guidance on refunds. Forums and social media saw an immediate surge of posts from people trying to figure out what was happening and how to get their money back. For academic labs running grant-funded projects on fixed timelines, the timing was particularly disruptive — qualifying a new vendor and validating compound equivalence is not a fast process. It can take weeks or months to establish that a replacement supplier's batches are analytically equivalent to the ones a study was built around.
The shutdown did not come out of nowhere. It followed months of escalating pressure that, in retrospect, made some form of exit look more likely than continued operation. That context matters for understanding not just what happened to Peptide Sciences, but what the research peptide market looks like going forward.
Why did Peptide Sciences shut down?
Multiple pressures converged. No single factor explains the closure, but the combination made continued operation increasingly untenable.
FDA enforcement volume. Starting in September 2025, the FDA issued more than 50 warning letters to peptide vendors, compounding pharmacies, and related operations — citing unapproved drug distribution, misbranding, and manufacturing deficiencies. That pace was unprecedented in the peptide sector. Warning letters are not just administrative notices; they carry the implicit threat of injunctions, product seizures, and criminal referrals if violations are not corrected. Fifty-plus letters in a compressed window signaled a sustained enforcement posture, not isolated action.
The Amino Asylum warehouse raid. In June 2025, federal agents physically raided the warehouse operations of Amino Asylum, a prominent research peptide vendor. The shift from paper enforcement to physical intervention was a clear signal that the FDA was willing to deploy its most aggressive tools. That event accelerated risk calculations across the industry.
Semaglutide shortage resolution. In February 2025, the FDA officially closed the semaglutide drug shortage designation. That resolution eliminated the legal framework that had allowed compounding pharmacies and some research peptide vendors to produce and sell GLP-1 analogs under shortage provisions of the Federal Food, Drug, and Cosmetic Act. For vendors whose revenue was significantly weighted toward GLP-1-related compounds — which Peptide Sciences' catalog was — that closure created a major operational problem.
The SAFE Drugs Act. Introduced in early 2026, the Strengthening and Advancing Federal Enforcement of Drugs Act proposed expanded FDA authority against entities distributing unapproved peptide products. It hadn't passed at the time of Peptide Sciences' closure, but its introduction with bipartisan support signaled where policy direction was heading.
Quality exposure from third-party testing. Finnrick Analytics and other independent testing organizations published reports that identified quality problems at multiple vendors, including Peptide Sciences. Retatrutide samples returned failing grades across 37 independently tested samples — that is a systemic pattern, not batch-level variance. CJC-1295 averaged 4.3 out of 10 in Finnrick's scoring. Counterfeit product detection appeared in late 2025 reports, suggesting some compounds shipped under recognized names did not match their labeled identity. When third-party testing data shows a compound does not meet advertised specifications, it does not just create reputational damage — it provides documentary evidence of potential misbranding, which amplifies regulatory exposure.
Together these factors created the kind of operating environment where the risk calculus points toward exit. Voluntary closure avoids the alternatives: waiting for a warning letter, a raid, or a legal proceeding.
What does the Peptide Sciences closure mean for the research market?
The immediate effect was the removal of roughly one million monthly researchers from an established supply chain overnight. That demand did not disappear. It redistributed across remaining suppliers, and that redistribution has reshaped the market in ways that are still playing out.
Supply chain disruption for active studies. Researchers mid-study had to choose between pausing their work and rapidly qualifying a new supplier. Switching vendors introduces variables around purity, synthesis methodology, and batch consistency that can compromise data continuity. Institutional labs with procurement protocols had additional administrative overhead — vetting, approving, and onboarding a replacement vendor through purchasing systems takes time even when nothing else is going wrong.
Quality scrutiny went up, not down. The third-party testing data that contributed to Peptide Sciences' closure did not stop circulating after the shutdown. If anything, the closure validated the scrutiny. Researchers started asking harder questions of remaining vendors: is your COA batch-specific or generic? Who ran the tests? Can you show me the chromatogram rather than just a purity number? The Finnrick retatrutide and CJC-1295 findings made the research community more skeptical of vendor self-reporting in ways that will likely be permanent.
Regulatory trajectory is clear. RFK Jr. publicly outlined plans for peptide reclassification that could fundamentally change how research compounds are categorized and sold. Whether those plans reach formal policy is uncertain, but the direction of travel is not. Increased FDA scrutiny, proposed legislation expanding enforcement authority, and the loss of shortage-related legal cover for GLP-1 compounds are structural changes to the operating environment — not temporary conditions.
Market consolidation. With the largest vendor gone, surviving vendors are absorbing displaced demand under a more scrutinized operating environment. Operations without solid quality systems, compliant supply chains, and defensible documentation practices are exposed to risk on two fronts: increased regulatory attention and a more demanding research customer base.
The demand for research-grade peptides from academic institutions, independent investigators, and organized research programs is not declining. The standard of what "research-grade" means in practice — from an analytical documentation and supply chain integrity standpoint — is rising.
What should researchers look for in a peptide supplier going forward?
The failures documented before and during the Peptide Sciences closure make clear what the minimum standards need to be. These are not aspirational requirements for premium procurement; they are the baseline for operating without exposing research programs to compound quality risk.
Batch-specific Certificate of Analysis included with every order. Not available on request — shipped automatically. Generic COAs reused across batches are a structural red flag; they mean the documentation is not actually tied to the compound you received. A valid COA contains a specific batch number, testing dates, analyst identification, and laboratory information. See How to Read a Certificate of Analysis for a detailed breakdown.
Independent HPLC verification and mass spectrometry on every compound. These are not optional analytical methods. HPLC quantifies purity; mass spectrometry confirms identity. Suppliers that report purity numbers without providing the underlying chromatographic data are asking you to trust their self-reporting — which is exactly what the Finnrick data showed cannot be trusted across the industry. Ask for the chromatogram, not just the percentage. More detail in Peptide Purity.
Endotoxin testing on all compounds. Bacterial endotoxin contamination is a real risk for compounds used in cell culture and sensitive in vitro assays. LAL testing or recombinant Factor C assays detect it. Suppliers that skip endotoxin testing are cutting corners on a safety-relevant quality parameter, not just an administrative one.
Cold-chain shipping as standard, not upgrade. Peptide degradation during ambient transit is documented in the published literature. A compound that leaves a warehouse at ≥99% purity and arrives degraded from heat exposure during shipping is not a ≥99% pure compound — it is an unknown mixture. Cold-chain packaging should be the default, not a fee-based add-on.
Documented purity threshold of ≥99%. Research-grade applications need this threshold to maintain reproducibility and minimize assay interference. Suppliers should publish their standards and produce compound-specific documentation to back them. Vendor claims without supporting data are not quality standards — they are marketing.
US-based operations. Domestic operations mean direct FDA accountability, faster shipping, and clear legal jurisdiction for disputes, returns, and quality complaints.
How is Cowboy Chems operating differently?
Cowboy Chems runs a 64-compound catalog built around a single operational principle: every batch gets independently tested before it ships, and the documentation comes with the order. Not as an add-on, not on request — as standard procedure.
The quality process on every compound: independent third-party HPLC verification for purity, mass spectrometry for identity confirmation, endotoxin testing for bacterial contamination. The resulting batch-specific COA ships with every order, tied to the batch number of the specific vials you received. Cold-chain packaging is included at the listed price — it is not a line item at checkout.
64 compounds rather than 190 because that is the scope that can be maintained to the same standard across the entire catalog. Adding volume by relaxing the verification bar would undermine the point of the whole operation. Every item a researcher orders from Cowboy Chems has cleared the same analytical pipeline as every other item — no exceptions, no tiered quality levels.
Cowboy Chems operates entirely within the United States. Browse the catalog at cowboychems.com/compounds.
The lesson from Peptide Sciences is not that the research peptide market is contracting. It is that the era of relying on brand recognition and catalog size as proxies for quality is over. Documentation is the new baseline. Suppliers who cannot show their work are increasingly exposed — to regulatory action and to a research community that now knows better than to take purity claims at face value.
What products did Peptide Sciences carry?
Their 190+ SKU catalog covered growth hormone secretagogues (ipamorelin, CJC-1295 DAC and no-DAC, sermorelin, hexarelin, GHRP-2, GHRP-6), metabolic compounds (GLP-1 receptor agonists, tirzepatide, semaglutide), tissue repair factors (BPC-157, TB-500), longevity compounds (epitalon, GHK-Cu, NAD+ precursors), and cognitive research compounds (selank, semax variants).
Cowboy Chems covers the primary research categories with a curated catalog. Compounds with direct equivalents include BPC-157, TB500, GHK-Cu, Ipamorelin, GLP-1, Sermorelin Acetate, CJC-1295 NO DAC, Epitalon, and NAD+. Full catalog at Browse all compounds.
Is Peptide Sciences coming back?
No current indication. The domain serves a static closure notice with no timeline, no contact information for updates, and no language suggesting a temporary pause. The regulatory conditions that made continued operation difficult — enforcement escalation, shortage loophole closure, incoming SAFE Drugs Act legislation — have not changed. There is no obvious path back to operation, and researchers waiting for a reopening are likely waiting for something that will not happen.
The practical response is to qualify a new supplier now, validate compound quality through independent testing, and build backup supply relationships before another single-source failure leaves a research program without what it needs.
The broader operating principle for research procurement after this closure: supply chains built around a single vendor carry structural risk regardless of how established that vendor appears. A company generating $7.4 million a month can disappear overnight without warning. Distribute procurement across multiple verified suppliers, keep your own COA and batch records independent of any vendor's systems, and stay current with the regulatory environment your supply chain operates in.
All compounds referenced in this article are research chemicals intended for laboratory and scientific research purposes only. Cowboy Chems does not sell products intended for human consumption. Researchers are responsible for ensuring compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.